Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep’s anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) – the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options.
“Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. “In multiple studies, pelareorep has repeatedly demonstrated its ability to engage the immune system to attack pancreatic cancer tumors, which has the potential to improve outcomes for patients battling this difficult-to-treat cancer.”
